

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source:

Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS. PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual - ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04): U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

ERROR DETECTED	SUCCESTED CO.
ATTN: NEW RULES C	SUGGESTED CORRECTION SERIAL NUMBER: 1000 971 B  USES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE  CICIS The number/lext at the end of each line "wrapped" down to the
1	DEASE DISREGARD ENGLISH "ALPHA" HEADERS WHICH WERF INCEPTED
Wrapped Nucl Wrapped Amir	cics The number/text at the end of each line "wespeed" down to !
	was retrieved in a word processor after creating it. Please adjust your right margin to 3: this will
2Invalid Line Le	ngth The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Ami	This includes white spaces
Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers:
Non-ASCII	The submitted file was a second
	The submitted file was not saved in ASCII(DOS) lext, as required by the Sequence Rules. Picase
SVariable Length	Sequence(s)
	Sequence(s)contain n's or Xaa's representing more than one sessidue. Per Sequence Rules, residue having variable least a single residue. Please present the maximum variable least present a single residue.
	each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing
GPatentIn 2.0 "bug"	A "bug" in Patentin version 2.0.1
oug	A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from animo acid  previously coded nucleic section.
	previously coded nucleic acid sequence. Please manually copy the relevant <220> <223> section to be missing from animo acid previously coded nucleic acid sequence. Please manually copy the relevant <220> <223> section to Artificial or Unknown seed sequence. This applies to the mandatory <220> <223> section to
	the subsequent amino acid sequence. Please manually copy the relevant <220>-<223> section to Artificial or Unknown sequences.
7Skipped Sequences	See Advances.
(OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence (1) SEQUENCE CHARACTERISE (1) SEQUENCE CHARACTERISE (2) SEQUENCE CHARACTERISE (3) SEQUENCE CHARACTERISE (4) SEQUENCE CHARACTERISE (5) SEQUENCE CHARACTERISE (6) SEQUENCE CHARACTERISE (7) SEQUENCE CHARACTERISE (8) SEQUENCE CHARACTERISE (9) SEQUENCE CHARACTERISE (1) SEQUENCE CHARAC
	(2) INFORMATION FOR SEQ ID NO X (insert SEQ ID NO where "X" is shown)  (x) SEQUENCE CHARACTERISTICS (Do not insert sex)
	(1) SEQUENCE CHARACTERISTICS (Do not insert any subheadings under this heading)  This sequence is interview.
	(xi) SEQUENCE DESCRIPTION SEQ ID NO X (insert SEQ ID NO where "X" is shown)  This sequence is intentionally skipped
8 Skipped Sequences	Please also adjust the "(ii) NUMBER OF SEQUENCES "response to include the skipped sequences.  Sequence(s)
(NEW RULES)	Sequence(s) missing If intentional, please insert the following lines for each skipped sequence < 400> sequence id number < 400> sequence id number
	2400> sequence id number
	000
9 Usc of n's or Xaa's	Use of nice and the second sec
(NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing  Per 1.823 of Sequence Rules have of 62205 (222)
1	cr 1.823 of Sequence Rules, use of <220>.<223> is MANDA TORY if n's or Xaa's are present cr 1.823 of Sequence Rules, use of <220>.<223> is MANDA TORY if n's or Xaa's are present cr 1.823 of Sequence Rules, the rest to the residue n or Xaa represents
10Invalid SMS> P	act 1822 co
Response s	Circlific name (Co). The only valid <213> responses are bloken.
. / "	cr 1.823 of Sequence Rules, the only valid <213> responses are. Unknown, Artificial Sequence, or.  Artificial Sequence.
11 V Usc of <220>	response is Unknown or
r s	Sc of <220> to <223> is MANDATORY if <213> "Organism" responses and responses
	se of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" of co" Federal Register, "Organism attendance of continuous and response is "Artificial Sequence" of co" Federal Register, "Organism attendance of co".
	Unknown." Please explain source of genetic material in <220> to <223> section.  cc "Federal Register," 00/01/1998, Vol. 63, No. 104, pp. 29641-323
LC2	ulting in missing man to orsk function of Patentln version 2.0. This cause
list	ulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence ing). Instead, please use "File Manager" or any other manual means to seem of
Misusc of n/X22 "n"	ing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
	can only represent a single nucleotide; "Xaa" can only represent a single amino acid
	AMC - Biotechnology Sustana B

AMC - Biotechnology Systems Branch - 09/09/2003



**IFWO** 

RAW SEQUENCE LISTING

3 <110> APPLICANT: Manoharan, Muthiah

DATE: 12/08/2004

PATENT APPLICATION: US/10/700,971B

TIME: 16:00:12

Input Set : A:\ISIC0009-101.txt

```
Baker, Brenda
     5
             Eldrup, Ann
             Bhat, Balkrishen
             Griffey, Richard H.
             Swayze, Eric E.
     9
             Crooke, Stanley T.
     12 <120> TITLE OF INVENTION: Conjugated Oligomeric Compounds and Their Use in Gene
             Modulation
     15 <130> FILE REFERENCE: US 10/700,971
C--> 17 <140> CURRENT APPLICATION NUMBER: US/10/700,971B
                                                                   Does Not Comply
     18 <141> CURRENT FILING DATE: 2003-11-04
                                                                   Corrected Diskette Needed
     20 <150> PRIOR APPLICATION NUMBER: US 10/616,241
     21 <151> PRIOR FILING DATE: 2003-07-09
     23 <150> PRIOR APPLICATION NUMBER: US 60/423,760
     24 <151> PRIOR FILING DATE: 2002-11-05
     26 <150> PRIOR APPLICATION NUMBER: US 10/078,949
     27 <151> PRIOR FILING DATE: 2002-02-20
     29 <150> PRIOR APPLICATION NUMBER: US 09/479,783
    30 <151> PRIOR FILING DATE: 2000-01-07
    32 <150> PRIOR APPLICATION NUMBER: US 08/870,608
    33 <151> PRIOR FILING DATE: 1997-06-06
    35 <150> PRIOR APPLICATION NUMBER: US 08/659,440
    36 <151> PRIOR FILING DATE: 1996-06-06
    39 <160> NUMBER OF SEQ ID NOS: 26
     41 <170> SOFTWARE: PatentIn version 3.2
     43 <210> SEO ID NO: 1
     44 <211> LENGTH: 16
     45 <212> TYPE: PRT
     46 <213> ORGANISM: Artificial Sequence
     48 <220> FEATURE:
    49 <223> OTHER INFORMATION: Antennapodia helix 3 Antp-HD
     51 <400> SEQUENCE: 1
    53 Arq Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
    58 <210> SEQ ID NO: 2
    59 <211> LENGTH: 13
     60 <212> TYPE: PRT
    61 <213> ORGANISM: Artificial Sequence
     63 <220> FEATURE:
     64 <223> OTHER INFORMATION: HIV Tat fragment
     66 <400> SEQUENCE: 2
    68 Gly Arg Lys Lys Arg Arg Gln Arg Arg Pro Pro Gln
```

## RAW SEQUENCE LISTING PATENT APPLICATION: US/10/700,971B DATE: 12/08/2004 TIME: 16:00:12

Input Set : A:\ISIC0009-101.txt

```
69 1
                                       10
72 <210> SEQ ID NO: 3
73 <211> LENGTH: 27
74 <212> TYPE: PRT
75 <213> ORGANISM: Artificial Sequence
77 <220> FEATURE:
78 <223> OTHER INFORMATION: Transporton: chimeric galanin and mastoporan
80 <400> SEQUENCE: 3
82 Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Pro Ile Asn Leu
85 Lys Ala Leu Ala Leu Ala Lys Lys Ile Leu
               20
89 <210> SEQ ID NO: 4
90 <211> LENGTH: 34
91 <212> TYPE: PRT
92 <213> ORGANISM: Artificial Sequence
94 <220> FEATURE:
95 <223> OTHER INFORMATION: Peptide - HSV VP22
97 <400> SEQUENCE: 4
99 Asp Ala Ala Thr Ala Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr
102 Glu Arg Pro Arg Ala Pro Ala Arg Ser Ala Ser Arg Pro Arg Pro
105 Val Glu
108 <210> SEQ ID NO: 5
109 <211> LENGTH: 18
110 <212> TYPE: PRT
111 <213> ORGANISM: Artificial Sequence
113 <220> FEATURE:
114 <223> OTHER INFORMATION: Amphiphilic peptide
116 <400> SEQUENCE: 5
118 Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys
119 1
121 Leu Ala
124 <210> SEQ ID NO: 6
125 <211> LENGTH: 27
126 <212> TYPE: PRT
127 <213> ORGANISM: Artificial Sequence
129 <220> FEATURE:
130 <223> OTHER INFORMATION: Signal sequence based peptide I
132 <400> SEQUENCE: 6
134 Gly Ala Leu Phe Leu Gly Trp Leu Gly Ala Ala Gly Ser Thr Met Gly
137 Ala Trp Ser Gln Pro Lys Lys Lys Arg Lys Val
                20
141 <210> SEQ ID NO: 7
142 <211> LENGTH: 16
143 <212> TYPE: PRT
144 <213> ORGANISM: Artificial Sequence
```

## RAW SEQUENCE LISTING DATE: 12/08/2004 PATENT APPLICATION: US/10/700,971B TIME: 16:00:12

Input Set : A:\ISIC0009-101.txt

```
146 <220> FEATURE:
147 <223> OTHER INFORMATION: Signal sequence based peptide II
149 <400> SEQUENCE: 7
151 Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro
155 <210> SEQ ID NO: 8
156 <211> LENGTH: 7
157 <212> TYPE: PRT
158 <213> ORGANISM: Artificial Sequence
160 <220> FEATURE:
161 <223> OTHER INFORMATION: SV40 antigen T nuclear localization signal
163 <400> SEQUENCE: 8
165 Pro Lys Lys Lys Arg Lys Val
169 <210> SEQ ID NO: 9
170 <211> LENGTH: 4
171 <212> TYPE: PRT
172 <213> ORGANISM: Artificial Sequence
174 <220> FEATURE:
175 <223> OTHER INFORMATION: Platelet activitating factor receptor of neutrophils
177 <400> SEQUENCE: 9
179 Met Leu Phe Tyr
180 1
183 <210> SEQ ID NO: 10
184 <211> LENGTH: 15
185 <212> TYPE: PRT
186 <213> ORGANISM: Artificial Sequence
188 <220> FEATURE:
189 <223> OTHER INFORMATION: Peptide - FXR2P
191 <400> SEQUENCE: 10
193 Pro Gln Arg Arg Asn Arg Ser Arg Arg Arg Phe Arg Gly Gln
194 1
                                         10
197 <210> SEQ ID NO: 11
198 <211> LENGTH: 7
199 <212> TYPE: PRT
200 <213> ORGANISM: Artificial Sequence
202 <220> FEATURE:
203 <223> OTHER INFORMATION: Angiogenin
205 <400> SEQUENCE: 11
207 Ile Met Arg Arg Arg Gly Leu
208 1
211 <210> SEQ ID NO: 12
212 <211> LENGTH: 11
213 <212> TYPE: PRT
214 <213> ORGANISM: Artificial Sequence
216 <220> FEATURE:
217 <223> OTHER INFORMATION: HIV-1 Rev
219 <400> SEQUENCE: 12
221 Leu Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu
```

## RAW SEQUENCE LISTING

DATE: 12/08/2004 PATENT APPLICATION: US/10/700,971B TIME: 16:00:12

Input Set : A:\ISIC0009-101.txt

```
222 1
                                         10
225 <210> SEQ ID NO: 13
226 <211> LENGTH: 11
227 <212> TYPE: PRT
228 <213> ORGANISM: Artificial Sequence
230 <220> FEATURE:
231 <223> OTHER INFORMATION: PKI-alpha
233 <400> SEQUENCE: 13
235 Glu Leu Ala Leu Lys Leu Ala Gly Leu Asp Ile
239 <210> SEQ ID NO: 14
240 <211> LENGTH: 11
241 <212> TYPE: PRT
242 <213> ORGANISM: Artificial Sequence
244 <220> FEATURE:
245 <223> OTHER INFORMATION: MAPKK
247 <400> SEQUENCE: 14
249 Asp Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu
250 1
253 <210> SEQ ID NO: 15
254 <211> LENGTH: 12
255 <212> TYPE: PRT
256 <213> ORGANISM: Artificial Sequence
258 <220> FEATURE:
259 <223> OTHER INFORMATION: Actin
261 <400> SEQUENCE: 15
263 Ala Leu Pro His Ala Ile Met Arg Leu Asp Leu Ala
264 1
267 <210> SEQ ID NO: 16
268 <211> LENGTH: 7
269 <212> TYPE: PRT
270 <213> ORGANISM: Artificial Sequence
272 <220> FEATURE:
273 <223> OTHER INFORMATION: Simian virus 40 large tumor antigen
275 <400> SEQUENCE: 16
277 Pro Lys Lys Lys Arg Lys Val
278 1
281 <210> SEQ ID NO: 17
282 <211> LENGTH: 13
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <223> OTHER INFORMATION: Dermaseptin
289 <400> SEQUENCE: 17
291 Ala Leu Trp Lys Thr Leu Leu Lys Lys Val Leu Lys Ala
295 <210> SEQ ID NO: 18
296 <211> LENGTH: 4
297 <212> TYPE: PRT
```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/700,971B

DATE: 12/08/2004 TIME: 16:00:12

Input Set : A:\ISIC0009-101.txt Output Set: N:\CRF4\12072004\J700971B.raw Artificial 298 <213> ORGANISM Sequence 300 <220> FEATURE: 301 <223> OTHER INFORMATION: Peptide 303 <400> SEQUENCE: 18 305 Lys Asp Glu Leu 306 1 308 <210> SEQ ID NO: 19 309 <211> LENGTH: 21 310 <212> TYPE: DNA erph Summary 311 <213> ORGANISM: Artificial Sequence 313 <220> FEATURE: 314 <223> OTHER INFORMATION: oligonucleotide 316 <400> SEQUENCE: 19 317 cgagaggcgg acgggaccgt t 320 <210> SEQ ID NO: 20 321 <211> LENGTH: 21 322 <212> TYPE: DNA 323 <213> ORGANISM: Artificial Sequence 325 <220> FEATURE: 326 <223> OTHER INFORMATION: oligonucleotide 328 <400> SEQUENCE: 20 329 ttgctctccg cctgccctgg c 21 332 <210> SEQ ID NO: 21 333 <211> LENGTH: 21 334 <212> TYPE: DNA 335 <213> ORGANISM: Artificial Sequence 337 <220> FEATURE: 338 <223> OTHER INFORMATION: oligonucleotide - cRaf targeter 340 <400> SEQUENCE: 21 21 341 augcauguca caggcgggat t 344 <210> SEQ ID NO: 22 345 <211> LENGTH: 21 346 <212> TYPE: DNA 347 <213> ORGANISM: Artificial Sequence 349 <220> FEATURE: 350 <223> OTHER INFORMATION: oligonucleotide - cRaf targeter 352 <400> SEQUENCE: 22 21 353 ucccgccugu gacaugcaut t 356 <210> SEQ ID NO: 23 357 <211> LENGTH: 18 358 <212> TYPE: DNA 359 <213> ORGANISM: Artificial Sequence 361 <220> FEATURE: 362 <223> OTHER INFORMATION: antisense oligonucleotide 364 <400> SEQUENCE: 23 365 tgggagccat agcgaggc 18 368 <210> SEQ ID NO: 24 369 <211> LENGTH: 20 370 <212> TYPE: DNA

VERIFICATION SUMMARY

DATE: 12/08/2004

PATENT APPLICATION: US/10/700,971B

TIME: 16:00:13

Input Set : A:\ISIC0009-101.txt

Output Set: N:\CRF4\12072004\J700971B.raw

1:17 M:270 C: Current Application Number differs, Replaced Current Application Number